<p>Nijmegen-based Aiosyn, a medical software company specializing in AI-assisted pathology, has completed a €2.4 million funding round. Participating investors include TNO Ventures and existing shareholders LUMO Labs, Health Innovations, and Oost NL. At the same time, Aiosyn is announcing a strategic partnership with TNO, the largest Dutch organization for applied scientific research.</p><p>With this investment and the new partnership, Aiosyn can accelerate the development and implementation of its AI solutions. The company aims to improve care for cancer patients by making pathological processes more efficient and accurate.</p><h2>Automating Complex Diagnostic Tasks</h2><p>The use of AI in healthcare is growing rapidly and offers opportunities to radically transform pathology. Aiosyn automates complex diagnostic tasks, enabling pathologists to make diagnoses faster and more consistently. Thanks to this funding, Aiosyn is expanding its offerings with new digital biomarkers and advanced tools for preclinical image analysis.</p><p>“This funding represents a major step forward for Aiosyn. It reaffirms our mission to bring AI innovation into practice and develop a new generation of algorithms that significantly improve decision-making regarding cancer treatment,” says Patrick de Boer, CEO of Aiosyn.</p><h2>Partnership with TNO</h2><p>The new partnership with TNO will advance both parties. Aiosyn will gain access to TNO’s research facilities and network to validate its AI software more quickly and bring it to market. TNO benefits from Aiosyn’s expertise in AI for preclinical contract research. This collaboration aligns well with TNO’s role as an investor in technologies that strengthen both its own research position and the Dutch tech ecosystem.</p><p>“Aiosyn is an excellent example of an innovative company that we are eager to support. This aligns with our ambition to help Dutch technology companies grow internationally and play a leading role in technological innovations,” said Hans Boumans, director of TNO Ventures.</p><p>Björn Schaap, Health Investment Manager at Oost NL: “The collaboration with TNO gives Aiosyn the opportunity to further develop its predictive biomarkers and deploy them more quickly in healthcare. These AI solutions have the potential to better tailor treatments to the specific needs of the patient.”</p>

Aiosyn Raises €2.4 Million to Accelerate AI Applications for Cancer Diagnostics